Histone deacetylase inhibitors enhance immunotherapy in lung cancer models, say researchers
Friday, April 1, 2016 - 08:20
in Health & Medicine
Several new immunotherapeutic antibodies that inhibit checkpoint receptors on T cells to restimulate the immune system to target tumors have been approved to treat advanced stage lung cancer and melanoma; however, only 20 percent of lung cancer patients show a response to these agents. Researchers have identified a class of drugs that improve the activity of immunotherapeutic antibodies by stimulating the movement of T cells into a tumor and enhancing their activity.